GlassScriptPhysician profile
Ling Lee
NPI 1538454277
$17,539.16
in general payments reported to CMS, 2019-2025
41 companies · $3,366 in 2025
The $3,366 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,619 · 2022: $2,781 · 2023: $4,018 · 2024: $3,755 · 2025: $3,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,139.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,504.25 | 2021-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $1,668.39 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,560.65 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,310.64 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,248.06 | 2021-2025 | |
| Gilead Sciences, INC. | $1,140.23 | 2022-2025 | Epclusa, Vemlidy |
| Novo Nordisk INC | $905.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $854.86 | 2021 | |
| Ibsa Pharma INC. | $623.87 | 2023-2025 | Licart, Tirosint, Tirosint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $598.22 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $531.07 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $495.74 | 2021-2024 | Trulance, Xifaxan |
| Kowa Pharmaceuticals America, INC. | $464.31 | 2021-2025 | Livalo, Seglentis, Zoryve |
| Nestle Healthcare Nutrition INC. | $437.40 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $409.72 | 2024-2025 | Voquezna |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $404.33 | 2021-2025 | Talicia, Talicia, Movantik |
| Merck Sharp & Dohme LLC | $394.73 | 2021-2025 | Vaxneuvance, Gardasil 9, Januvia |
| Exact Sciences Corporation | $371.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ironwood Pharmaceuticals, INC | $228.65 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $216.62 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $197.28 | 2024-2025 | Ibsrela |
| Amarin Pharma, INC. | $176.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $157.04 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $86.56 | 2025 | Pyrukynd |
| Hikma Pharmaceuticals USA | $76.87 | 2021-2023 | Ryaltris, Mitigare |
| Xeris Pharmaceuticals, INC. | $73.48 | 2021-2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $55.87 | 2022 | |
| Pfizer INC. | $47.14 | 2022-2023 | |
| Dexcom, INC. | $36.01 | 2022-2023 | Dexcom G6 Transmitter |
| Radius Health, INC. | $32.30 | 2021 | |
| Allergan, INC. | $27.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.79 | 2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $24.71 | 2022 | |
| Sanofi Pasteur INC. | $24.70 | 2022 | |
| Alkermes, INC. | $23.31 | 2021 | |
| Qiagen, LLC | $19.64 | 2024 | |
| Qol Medical, LLC | $18.35 | 2024 | Sucraid |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.85 | 2023 | Ztlido |
| Eyevance Pharmaceuticals LLC | $16.78 | 2021 | |
| Horizon Therapeutics Plc | $16.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.